U.S. markets close in 1 hour 19 minutes
  • S&P 500

    3,444.03
    +24.58 (+0.72%)
     
  • Dow 30

    28,403.68
    +100.22 (+0.35%)
     
  • Nasdaq

    11,418.61
    +54.01 (+0.48%)
     
  • Russell 2000

    1,627.69
    +16.65 (+1.03%)
     
  • Crude Oil

    41.19
    +1.24 (+3.10%)
     
  • Gold

    1,895.20
    +4.40 (+0.23%)
     
  • Silver

    23.95
    +0.05 (+0.23%)
     
  • EUR/USD

    1.1759
    -0.0010 (-0.08%)
     
  • 10-Yr Bond

    0.7700
    -0.0150 (-1.91%)
     
  • GBP/USD

    1.2934
    +0.0017 (+0.13%)
     
  • USD/JPY

    106.0260
    +0.0560 (+0.05%)
     
  • BTC-USD

    10,868.94
    +199.63 (+1.87%)
     
  • CMC Crypto 200

    231.32
    +14.57 (+6.72%)
     
  • FTSE 100

    5,978.03
    +31.78 (+0.53%)
     
  • Nikkei 225

    23,647.07
    +224.25 (+0.96%)
     

Wise Therapeutics Raises Pre-Seed Funding; Releases Free Version of Personal Zen for Android and iOS Free to Consumers

The evidence-based app for stress and anxiety will be widely available to support mental wellness during COVID-19 crisis and beyond

NEW YORK, Oct. 8, 2020 /PRNewswire/ -- Wise Therapeutics, a digital therapeutics company created to improve access to effective mental health treatments using digital interventions, announced the closing of its first outside funding of $525,000 to support Android development and early rollout of its flagship app Personal Zen for stress and anxiety. The app offers a game-like cognitive training algorithm that is based on years of clinical research by its co-founder Dr Tracy Dennis-Tiwary. Its pre-seed funding round was led by SeedLink SL, an early stage VC investor focusing on digital health and technology solutions, including additional investors Teem Ventures, a NYC-based venture development studio, and Reshma Saujani, a women's leadership advocate and the Founder of Girls Who Code.

Wise Therapeutics, Inc. (PRNewsfoto/Wise Therapeutics, Inc.)
Wise Therapeutics, Inc. (PRNewsfoto/Wise Therapeutics, Inc.)

In the United States, more people suffer from behavioral and mental health problems than any other disease category. The current pandemic has further highlighted the need for more accessible treatments, with 53% of adults in the US reporting increasing feelings of stress and worry as of July 2020. To help serve this need, a free version of Personal Zen is being offered on iOS and released on Android for the first time. Additional features and content will be offered to healthcare organizations to help identify, support and manage the care of individuals burdened by stress in the workplace and suffering from chronic and episodic health conditions.

"Our true mission is to provide universal access to mental wellness," shared Dr. Tracy Dennis-Tiwary, Co-founder and CEO of Wise Therapeutics. "We have an incredible opportunity and a responsibility as scientists to take the ideas we create in the lab and put them in the hands of people who need them most." Personal Zen's clinically validated algorithm has over twenty years of research showing its efficacy in reducing stress and anxiety and helping build resilience to stress. Designed to radically lower the barriers to engagement and access, Personal Zen is effective when used for just a few minutes a day, a few days a week.

"Throughout the global pandemic, people have been searching for effective resources to help improve resulting stress and anxiety," said Tim Juergens, Co-founder and General Manager of SeedLink SL. "We are excited to get behind Wise Therapeutics and support their journey to impact lives with clinically validated digital therapeutics that are accessible, effective, and easy to use throughout and well after this pandemic."

Download Personal Zen today from Apple's App Store and Google Play Store.

Learn more about Wise Therapeutics at www.WiseDTx.com.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/wise-therapeutics-raises-pre-seed-funding-releases-free-version-of-personal-zen-for-android-and-ios-free-to-consumers-301148961.html

SOURCE Wise Therapeutics, Inc.